| 2.09 -0.09 (-4.13%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.94 | 1-year : | 3.5 |
| Resists | First : | 2.51 | Second : | 3 |
| Pivot price | 2.32  |
|||
| Supports | First : | 1.74 | Second : | 1.44 |
| MAs | MA(5) : | 2.06 |
MA(20) : | 2.39 |
| MA(100) : | 3.1 |
MA(250) : | 4.74 |
|
| MACD | MACD : | -0.2  |
Signal : | -0.2 |
| %K %D | K(14,3) : | 29.8 |
D(3) : | 29.1 |
| RSI | RSI(14): 40.6 |
|||
| 52-week | High : | 13.31 | Low : | 1.7 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CTCX ] has closed above bottom band by 25.1%. Bollinger Bands are 12.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.09 - 2.1 | 2.1 - 2.11 |
| Low: | 2.06 - 2.08 | 2.08 - 2.09 |
| Close: | 2.07 - 2.09 | 2.09 - 2.11 |
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
Tue, 26 Mar 2024
CTCX Stock Quote Price and Forecast - CNN
Thu, 21 Mar 2024
Carmell Therapeutics selling Axolotl Biologix subsidiary - TipRanks.com - TipRanks
Mon, 26 Feb 2024
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Markets Insider
Tue, 12 Sep 2023
Moonshot Client Axolotl Announces Merger with Carmell Therapeutics, Elevating the Field of Regenerative Medicine - PR Newswire
Tue, 05 Sep 2023
Carmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organizational ... - Yahoo Finance
Mon, 07 Aug 2023
Carmell Therapeutics begins public trading - Pittsburgh Post-Gazette
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 39 (%) |
| Held by Institutions | 13.7 (%) |
| Shares Short | 14 (K) |
| Shares Short P.Month | 25 (K) |
| EPS | -1.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.07 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -10 % |
| Return on Equity (ttm) | -176.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -1.37 |
| PEG Ratio | 0 |
| Price to Book value | 1.95 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|